Sequence of Radiation and Targeted Therapy in Brain Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

570 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-01

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC

NCT04193007

Non Small Cell Lung Cancer Brain Metastases

UNKNOWN PHASE2

Focal Intraoperative Radiotherapy of Brain Metastases

NCT03789149

Brain Metastases, Adult Central Nervous System Metastases

TERMINATED PHASE2

Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases

NCT04178330

Brain Metastases

COMPLETED NA

Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases

NCT05871307

Brain Metastases Radiotherapy

RECRUITING PHASE2

Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial

NCT06974370

Brain Metastases, Adult Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The upfront radiotherapy group

No interventions assigned to this group

The upfront targeted-therapy group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Had histologically proven primary cancer.
* Had newly diagnosed brain metastases in contrast-enhanced MRI.
* Brain metastases focus should be measurable.
* All the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors.
* Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases.

Exclusion Criteria

* Patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail
* Patients with leptomeningeal metastases at first diagnosis.
* Had synchronous or metachronous malignancies that might affect survival.
* Had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures.
* Had incomplete sociodemographic and/or clinicopathologic baseline data

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No